VRTX Stock Overview
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for VRTX from our risk checks.
Vertex Pharmaceuticals Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$354.28 |
| 52 Week High | US$367.00 |
| 52 Week Low | US$276.57 |
| Beta | 0.51 |
| 1 Month Change | 1.05% |
| 3 Month Change | 2.10% |
| 1 Year Change | 24.99% |
| 3 Year Change | 32.11% |
| 5 Year Change | 83.81% |
| Change since IPO | 7,772.89% |
Recent News & Updates
Recent updates
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jul 31
We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease
Jul 03An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 22% Undervalued
Apr 30With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Apr 03An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 24% Undervalued
Jan 23If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity
Jan 02Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 47%?
Oct 24Vertex to advance two AAT correctors to potentially treat rare, genetic disease
Oct 11Do Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings Warrant Your Attention?
Oct 02Vertex in licensing agreement with MaxCyte to use platform for gene editing candidate
Sep 28Vertex Pharmaceuticals: Clinical Data Supports A Favorable Long-Term Growth Outlook
Sep 19Vertex wins FDA label expansion for cystic fibrosis drug to add younger children
Sep 02Vertex: CF Monopoly, Looking To Expand
Aug 05Vertex to run late-stage studies for pain therapy in 4Q 2022
Jul 22Vertex announces ViaCyte acquisition to expand diabetes pipeline
Jul 11Vertex says FDA lifted clinical hold on trial for stem cell-based diabetes therapy
Jul 05Vertex: In A Class By Itself, Promising Pipeline Of Game-Changing Drugs
Jun 28An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 44% Undervalued
Jun 27AbbVie's Failure Solidifies Vertex Pharmaceuticals' Cystic Fibrosis Leadership Position
Jun 06Vertex: Q1 Results Solid, If Unspectacular, But Pipeline Progress Makes Bull Case
May 06Vertex Stock: Priced At A Premium For Good Reason, Although A Dip May Be Coming
Apr 07Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Intrinsic Value Is Potentially 87% Above Its Share Price
Mar 28Vertex: More Opportunities Ahead
Mar 22Why Vertex Is One Of The Best Biotech Stocks To Own
Jan 31Vertex: Growth At An Acceptable Valuation
Jan 25Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 50% Below Their Intrinsic Value Estimate
Dec 27Vertex: Waiting For The Pipeline Success
Dec 21Recent Pipeline Updates Show Vertex Is Not Just About Cystic Fibrosis
Dec 07Reasons To Buy Vertex Below $200
Sep 29Shareholder Returns
| VRTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.5% | -0.5% | -1.5% |
| 1Y | 25.0% | 10.8% | 13.8% |
Return vs Industry: VRTX exceeded the US Biotechs industry which returned 10.8% over the past year.
Return vs Market: VRTX exceeded the US Market which returned 13.8% over the past year.
Price Volatility
| VRTX volatility | |
|---|---|
| VRTX Average Weekly Movement | 2.5% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in US Market | 14.3% |
| 10% least volatile stocks in US Market | 2.5% |
Stable Share Price: VRTX is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: VRTX's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 4,800 | Reshma Kewalramani | https://www.vrtx.com |
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company’s pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial.
Vertex Pharmaceuticals Incorporated Fundamentals Summary
| VRTX fundamental statistics | |
|---|---|
| Market Cap | US$91.44b |
| Earnings (TTM) | US$3.36b |
| Revenue (TTM) | US$9.51b |
27.2x
P/E Ratio9.6x
P/S RatioIs VRTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VRTX income statement (TTM) | |
|---|---|
| Revenue | US$9.51b |
| Cost of Revenue | US$4.02b |
| Gross Profit | US$5.49b |
| Other Expenses | US$2.12b |
| Earnings | US$3.36b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 13.04 |
| Gross Margin | 57.75% |
| Net Profit Margin | 35.40% |
| Debt/Equity Ratio | 0% |
How did VRTX perform over the long term?
See historical performance and comparison